Clinically available drugs active against Epstein–Barr virus (EBV) and other human herpes viruses are limited to those targeting viral DNA replication. To identify compounds directed against other steps in the viral life cycle, we searched for drugs active against the EBV SM protein, which is essential for infectious virus production. SM has a highly gene-specific mode of action and preferentially enhances expression of several late lytic cycle EBV genes. Here we demonstrate that spironolactone, a mineralocorticoid receptor antagonist approved for clinical use, inhibits SM function and infectious EBV production. Expression of EBV viral capsid antigen is highly SM dependent, and spironolactone inhibits viral capsid antigen synthesis and capsid formation, blocking EBV virion production at a step subsequent to viral DNA replication. In addition, spironolactone inhibits expression of other SM-dependent genes necessary for infectious virion formation. We further demonstrate that molecules structurally related to spironolactone with similar antimineralocorticoid blocking activity do not inhibit EBV production. These findings pave the way for development of anti-herpes virus drugs with new mechanisms of action directed against SM and homologous essential proteins in other herpes viruses.
To read the full article click HERE.
Date of publication: 17 February 2016; Proceedings of the National Academy of Sciences
Author information: Dinesh Verma (1); Jacob Thompson (1); & Sankar Swaminahan (1)
(1) Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT84132